Add like
Add dislike
Add to saved papers

Baricitinib is safe and effective for treatment of refractory juvenile idiopathic arthritis

2 Minute Medicine 2023 September 15

1. Time to disease flare was significantly shorter in the placebo group versus baricitinib.

2. There was no difference in serious adverse events between the baricitinib and placebo groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Juvenile idiopathic arthritis (JIA) is defined by the onset of polyarticular joint pain before age 16 and can severely affect an individual’s quality of life. First-line treatment for JIA includes nonsteroidal anti-inflammatory drugs (NSAIDs) and biologic disease-modifying antirheumatic drugs (DMARDs), however, many patients with JIA continue to experience refractory symptoms. This randomized controlled trial aimed to assess the safety and efficacy of baricitinib, an oral Janus kinase 1/2-selective inhibitor, versus placebo, in patients with refractory JIA. The primary outcome of this study was time to disease flare in the withdrawal period, while key secondary outcomes included the proportion of patients with a flare and change in the Juvenile Arthritis Disease Activity Score 27 (JADAS-27). According to study results, baricitinib was effective in reducing JIA flare rates in patients without increasing rates of serious adverse events among patients with JIA refractory to standard therapy. Although this study was well done, it was limited by a small follow-up period, thus affecting the validity of the findings.

Click to read the study in The Lancet

Relevant Reading: Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

In-depth [randomized-controlled trial]: Between Dec 17, 2018, and Mar 3, 2021, 263 patients were screened for eligibility across 75 centres in 20 countries. Included were patients aged 2 to <18 years with various forms of JIA (polyarticular, extended oligoarticular, enthesitis-related, and juvenile psoriatic arthritis) refractory to standard treatments. Altogether, 220 patients were included in the final analysis. The primary outcome of time to disease flare was significantly longer in the baricitinib group versus placebo (not evaluable in baricitinib due to <50% flare event vs. 27.14 weeks in placebo, hazard ratio [HR] 0.241, 95% confidence interval [CI] 0.128-0.453, p<0.0001). Serious adverse events were comparable in the baricitinib and placebo groups (5% vs. 4%, incidence rate [IR] 9.7 vs. 10.2 per 100 patient-years at risk) with pulmonary embolism (1%, IR 2.4) in the baricitinib group being most common. Overall, findings from this study suggest that baricitinib may be effective for the treatment of refractory JIA and possesses a tolerable safety profile.

Originally Published By 2 Minute Medicine®. Reused on Read by QxMD with permission.

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Add to Saved Papers

Get 1-tap access

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app